Colloidal oatmeal: 1% held its own against a prescription cream — but the people who ran the trials sell it

The 2017 trial randomised 90 patients aged 6 months to 18 years with mild-to-moderate atopic dermatitis to a 1% colloidal oatmeal cream or a prescription barrier cream (45 each), double-blind, over three weeks.

At week 3 on the Eczema Area and Severity Index, the oatmeal cream was non-inferior to the prescription cream (non-inferiority margin 1.5; adjusted mean change from baseline, ITT 0.18 [95% CI −0.35, 0.70]). Investigator assessment (IGADA) and itch on a visual analogue scale improved in both groups, and no safety issues were identified.

The 2023 paper is not a new trial. It reports the Black/African American subgroup of 49 from that same study. At week 3, mean EASI change was −2.4 (SD 1.7) with the oatmeal cream and −2.1 (SD 2.3) with the barrier cream.

Why that distinction matters: two papers are not two trials. Same participants, same allocation, same three weeks. Counting papers as evidence would make this ingredient look twice as well supported as it is. Keeping a separate trial identifier is exactly why this site does that.

Also, the comparator is a prescription cream. The question this design answers is not 'does oatmeal work' but 'is it no worse than the prescription cream'.

The 2020 trial randomised patients with mild-to-moderate eczema to a 1% colloidal oat eczema cream (30) or a standard, non-fragranced moisturiser (31). Fourteen days of treatment followed by seven days of observation; 61 completed.

At day 14 the oat cream reduced mean EASI by 51% and the Atopic Dermatitis Severity Index by 54%.

Two things need separating here.

• What was significant: the oat cream significantly improved skin pH, barrier function and hydration from baseline. The standard moisturiser improved hydration only.
• What was a 'trend': at lesion sites, there were trends towards lower prevalence of Staphylococcus species and higher microbiome diversity. That is the word the authors used — they did not call it significant.

Marketing sometimes cites this study for 'improves the skin microbiome'. What the source says is trends. The barrier findings are firmer; the microbiome ones are not there yet.

This item is not about a result. It is about where the evidence comes from.

The author affiliations on all three papers above point to the same place. The 2023 paper states its affiliation outright as 'a subsidiary of Kenvue' — the company that sells products using this ingredient. The authors of the 2017 and 2020 papers sit at the same address (Skillman, NJ).

This does not mean the results are wrong. They are double-blind, randomised, and properly designed.

But on this site's evidence ladder, an item funded entirely by industry cannot be graded 'strong' — because there is no independent confirmation. We found no trial in which someone without a commercial interest asked the same question again.

And there is a bigger blank. In all three, the comparator is another cream — a prescription barrier cream, a standard moisturiser. No trial included an untreated arm.

In eczema that limitation bites hard, because it is a condition that improves when you apply almost anything consistently. The 2020 result showing that the standard moisturiser also improved hydration demonstrates exactly that.